ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair

Trial Profile

ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2016

At a glance

  • Drugs Veliparib (Primary) ; Mitomycin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 09 Feb 2016 Results published in the Journal of the National Cancer Institute
    • 13 Jul 2015 Planned primary completion date changed from 1 Jun 2015 to 1 May 2016 as reported byClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top